Lisette Hilton

Rare aggressive cutaneous lymphoma puts patients at risk of thyroid and non-lymphocytic leukemia second primary malignancies, researchers say.

Experts discuss the impact of misinformation in medicine at the current ACAAI annual scientific meeting.

Mark G. Lebwohl, MD, presents on what dermatologists need to know about the newest psoriasis studies during the Fall Clinical Dermatology Conference.

Cantharidin 0.7% could be an emerging standard for molluscum treatment.

Optimizing rosacea treatment outcomes isn’t only about papules and pustules. Facial erythema needs to be part of an effective management plan.

COVID-19’s lingering impact brings new considerations for treatment regimens for pediatric patients with psoriasis.

As COVID-19 eases, the FDA is breaking through its backlog and clinical trials are moving forward, opening the way for a new wave of treatments.

The pro-inflammatory transcription factor is critical for the expression of IL-23, which is known to play a role in psoriasis.

Experts present detailed guidelines on how to diagnose and treat common skin diseases and conditions in the Asian American population.

Experts evaluate efficacy and safety of regenerative skin care products.

Study findings show calcipotriene-betamethasone foam to be safe and moderately effective in skin of color patients with psoriasis but failed to meet several secondary endpoints and to demonstrate statistically significant changes.

The decision between surgical and nonsurgical options for chin augmentation continues to be a debate, but according to Michael Somenek, MD, this can be easily settled with personalized patient consultation.

Recently approved treatments for acne are focused on decreasing activity within the sebaceous gland.

The investigational neuromodulator, evaluated in clinical trials as a treatment for glabellar lines and as a combined therapy for glabellar, dynamic forehead, and lateral canthal lines, is quickly nearing an approval by the FDA.

Cancer staging systems for squamous cell carcinoma have helped improve dermatologists’ ability to accurately stage the cancer, according to one expert.

In the Moderna coronavirus disease 2019 (COVID-19) vaccine trials, 3 participants reported facial or lip swelling after receiving the vaccine. ASDS guidelines state that patients with a history of dermal filler injections should not void vaccinations

Findings from two recent pilot studies suggest 1927 nm fractional thulium fiber laser-assisted topical tranexamic acid delivery is a safe, effective melasma treatment option.

A recent study found patients with high baseline cardiovascular risk who had taken ustekinumab were at increased risk for developing severe cardiovascular events following treatment.

Dermatologists should consider assessing melasma patients for increased vascularity and include antivascular treatments to improve outcomes among patients whose lesions have a vascular component. 

Researchers are looking at treating blastic plasmacytoid dendritic cell neoplasm (BPDCN), an aggressive hematolymphoid malignancy, with investigational agents equipped with different mechanisms of action, including XmAb14045 and IMGN632.

A recently published article details the clinical and biological features, and patient outcomes of blastic plasmacytoid dendritic cell neoplasm (BPDCN), a rare hematopoietic malignancy.

B-cell lymphoma-2 inhibitor venetoclax has shown in clinical studies to improve symptoms with minimal toxicity in patients with cutaneous blastic plasmacytoid dendritic cell neoplasm (BPDCN), an aggressive hematologic cancer that can be rapidly fatal without treatment.

A majority of psoriasis patients in phase 3 clinical trials for biologics are white, says authors of a recent study. As ethnicity and race may play a role in response to biologics, researchers emphasize need for more diversity in clinical trials.

Cysteamine cream and tranexamic acid mesotherapy demonstrated similar efficacy but yielded different safety results when being compared as a treatment for melasma, according to a recently published study.

Lasers typically used for tattoo removal are on the rise as a possible treatment for melasma, with the novel 730 nm picosecond laser (PicoWay, Candela) being the most recently studied device which showed to be safe and effective for treating benign pigmented lesions.

Several CD123-targeted therapies have been in development following the FDA’s 2018 approval of tagraxofusp for the treatment of blastic plasmacytoid dendritic cell neoplasm (BPDCN), but important questions remain when it comes to targeting CD123 in myeloid malignancies.

Today's universal improvement in melanoma survival is encouraging. But the reality is racial disparities aren’t going away and in some cases are getting worse.

The problem of sensitive skin has risen dramatically in the last decade, highlighting the need for affordable, effective and scientifically-formulated and tested products designed especially for people with sensitive skin.

An overwhelming majority of subjects in phase 3 psoriasis clinical trials are Caucasian, leaving unanswered questions about how one’s ethnicity or race might impact the safety and efficacy of today’s psoriasis treatments, according to a research letter published August 7 in the British Journal of Dermatology.

Findings from a recent study support current recommendations to treat patients with BPDCN with tagraxofusp or hyper-CVAD as first-line treatments, then with allogeneic stem cell transplant if patients are eligible.